Review Article

Association between HLA-DP Gene Polymorphisms and Cervical Cancer Risk: A Meta-Analysis

Lin Cheng,1,2 Yan Guo,3 Shipeng Zhan,2 and Peiyuan Xia2

1Institute of Burn Research, The First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing 400038, China
2Department of Pharmacy, The First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing 400038, China
3Department of Infectious Disease, The First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing 400038, China

Correspondence should be addressed to Peiyuan Xia; py_xia2013@163.com

Received 17 October 2017; Revised 9 April 2018; Accepted 30 April 2018; Published 13 June 2018

1. Introduction

Cervical cancer is the second most commonly diagnosed cancer and third leading cause of cancer-related mortality among women in less developed countries [1]. In only one year, 2012, there were an estimated 527,600 new cervical cancer cases and 265,700 deaths worldwide [2]. Human papillomavirus (HPV) has been widely accepted as a risk factor of cervical carcinogenesis [3]; however, HPV infections have developed to persistent infection in only a very few women and to cervical cancer in an even smaller proportion [4]. Many infected women have spontaneously HPV clear through immune response [5], suggesting that other factors such as host factors may contribute to the progression of the disease[6]. Understanding the relationship between host factors and cervical cancer risk is necessary to comprehend the striking heterogeneity in anti-HPV and provide evidence for rational design of host-directed therapy.

Human leukocyte antigens (HLA) Class II genes, which encoded by DR, DQ, and DP genes, are mainly expressed in antigen presentation cells. They are essential for the presentation of viral peptides to the immune system, including HPV [18, 19]. HLA II genes are highly polymorphic, and genetic variability of the HLAII alleles may lead to variations of the antigen-recognition of antigen presentation cells, thus resulting in the body being susceptible or resistant to HPV infection and consequentially affecting the results of the infection [19–21]. So far, more than 200 articles focusing on
the relationship of HLA and cervical cancer have been published in the past 10 years; meanwhile many researches have investigated the relationship of HLA gene polymorphisms and cervical cancer risk [22, 23]. More importantly, HLA-DQA1, DQB1, and DRB1 gene polymorphisms have been found associated with the risk of cervical cancer in meta-analysis [24–26].

Recently, a number of genome-wide association studies (GWAS) have been performed to investigate the association between specific HLA II alleles and cervical cancer in Asia and Europe [7, 11, 13, 15], and many case-control studies have reported the association of HLA-DPA1, DPB1, and DPB2 with cervical cancer. Based on these studies, many alleles like HLA-DPB1*02:02, DPB1*03:01, DPB1*04:02, DPB1*05:01, DPB1*13:01, rs9277535 (DPB1), rs4282438 (DPB2), rs3117027 (DPB2), and rs3077 (DPA1) were reported to be significantly associated with cervical cancer [8–10, 12, 14, 16, 17]. However, the results are inconclusive and controversial. For example, only in four GWAS focusing on investigating of susceptibility loci for cervical cancer, the results of associations between specific HLA II alleles and cervical cancer risk were not consistent [7, 11, 13, 15]. Since a single-center study may have an inadequate sample size and lack statistical power to obtain reliable conclusions and no previous meta-analyses in the literature had covered this research question, we conducted a meta-analysis of all eligible studies including the four GWAS to obtain a more precise estimation of the associations.

2. Methods

2.1. Search Strategy. To identify eligible studies, we systematically searched PubMed, EMBASE, ScienceDirect, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wanfang databases. The keywords used for search were as follows: “cervical cancer” or “cervical carcinoma” or “uterine cervical carcinoma” and “HLA-DP” or “human leukocyte antigen” or “HLA antigens”. There were no limitations on language and publication year. The last search was updated on July 30, 2017. We also retrieved the references of all relevant articles to identify additional eligible studies.

2.2. Inclusion and Exclusion Criteria. Eligible studies must meet the following inclusion criteria: (a) case-control studies; (b) evaluating the association between HLA-DP gene polymorphisms (DPB1*02:01, DPB1*02:02, DPB1*03:01, DPB1*04:01, DPB1*04:02, DPB1*05:01, DPB1*13:01, rs4282438, rs9277535, rs3077, and rs3117027) and cervical cancer (including cervical cancer in situ) risk; (c) available genotype frequencies; and (d) the genotype distribution in control groups being in the Hardy-Weinberg equilibrium (HWE).

Exclusion criteria of studies were as follows: (a) letters, reviews, and case reports; (b) lack of genotype frequency data; and (c) duplicate publication. In addition, if multiple studies had overlapping data, only those with complete data were included.

2.3. Data Extraction. Two authors independently selected the relevant articles and extracted the following data: first author’s name, publication year, country, genotyping methods, number of cases and controls, genotype and allele frequency, and evidence of HWE in controls. Any controversy was resolved by discussion between the authors.

2.4. Statistical Analysis. HWE in the control group of each study was examined by goodness-of-fit chi-square test, and P HWE< 0.05 was considered as a deviation from HWE. The association between HLA-DP gene polymorphisms (DPB1*02:01, DPB1*02:02, DPB1*03:01, DPB1*04:01, DPB1*04:02, DPB1*05:01, DPB1*13:01, rs4282438, rs9277535, rs3077, and rs3117027) and cervical cancer risk was evaluated by pooled OR and 95% CI. The Z test was used to investigate the significance of the pooled OR, and P Z<0.05 was considered as statistically significant. The heterogeneity between studies was assessed by the chi-square-based Q-test and I2 tests. If the P< 0.05 or I2 >50%, indicating the existence of between-study heterogeneity, then the random-effects model was used to calculate the pooled ORs; otherwise, the fixed-effects model was applied to the analysis. The stability of the result was evaluated by sensitivity analysis. Egger’s test and Begg’s test were used to determine the publication bias among studies, and P E<0.05 was considered significant. All statistical tests were performed with the STATA software (version 12.0; StataCorp, College Station, TX, USA).

3. Results

3.1. Study Selection and Characteristics. The study selection process is shown in Figure 1. A total of 614 articles were initially retrieved from electronic databases including PubMed,
EMBASE, ScienceDirect, Web of Science, CNKI, and Wanfang databases. After reviewing the titles, abstracts, and full text, we excluded 603 irrelevant studies. Finally, 11 articles published between 2007 and 2016 assessing the association between HLA-DP gene polymorphism and cervical cancer risk were included in the current meta-analysis. The main characteristics of all eligible studies are shown in Table 1. All the included studies were conducted in Europe or Asia. For HLA-DP alleles, there were three articles included. For different allele, the number of cases ranged from 882 to 5008, and the number of controls ranged from 1150 to 9322 (Table 2).

### Table 1: Main characteristics of all studies included in the meta-analysis.

| First author | Year | Country | Case  | Control | Genotyping method          | Polymorphisms                                      |
|--------------|------|---------|-------|---------|-----------------------------|-----------------------------------------------------|
| Miura K [7]  | 2016 | Japan   | 214   | 288     | PCR-SBT                     | DPB1*02:01, DPB1*02:02, DPB1*03:01, DPB1*04:01, DPB1*04:02, DPB1*05:01, DPB1*13:01, rs4282438 |
| Jia M [8]    | 2016 | China   | 593   | 4074    | TaqMan assay                | rs4282438, rs9277535, rs3117027, rs3077              |
| Yang YC [9]  | 2015 | Taiwan  | 473   | 676     | PCR, sequencing             | DPB1*02:01, DPB1*02:02, DPB1*03:01, DPB1*04:01, DPB1*05:01, DPB1*13:01, rs9277535 |
| Chen D [10]  | 2014 | Sweden  | 1034  | 3948    | PCR, sequencing             | DPB1*02:01, DPB1*03:01, DPB1*04:01, DPB1*13:01, rs4282438, rs3117027 |
| Chen D [11]  | 2013 | Sweden  | 2215  | 5072    | GENios Pro platform         | rs3117027                                           |
| Jiang J [12] | 2013 | China   | 2317  | 2109    | TaqMan assay                | rs9277535, rs3077                                    |
| Shi Y [13]   | 2013 | China   | 5531  | 10224   | Affymetrix Axiom Genome-Wide CHB1 Array | rs4282438                                           |
| Zhang K [14] | 2013 | China   | 831   | 573     | TaqMan assay                | rs9277535, rs3077                                    |
| Ivansson EL [15] | 2011 | Sweden | 1076  | 1426    | Affymetrix Genome-Wide Human SNP Array | DPB1*02:01, DPB1*03:01, DPB1*04:01, DPB1*04:02, DPB1*05:01 |
| Liang J [16] | 2008 | China   | 126   | 88      | PCR-SBT                     | DPB1*02:002, DPB1*02:02, DPB1*03:01, DPB1*04:01, DPB1*04:02, DPB1*05:01, DPB1*13:01 |
| Wu Y [17]    | 2007 | China   | 133   | 98      | PCR-SBT                     | DPB1*02:02, DPB1*02:02, DPB1*03:01, DPB1*04:01, DPB1*04:02, DPB1*05:01, DPB1*13:01 |

PCR-SBT: polymerase chain reaction sequence-based typing; SNP: single nucleotide polymorphisms.

3.2. Quantitative Data Synthesis. The results of this meta-analysis are shown in Tables 2, 3, and 4. Based on the results, we found that HLA-DPB1*03:01 was significantly associated with an increased risk of cervical cancer (OR=1.252, 95%CI: 1.161-1.403, Pz=0.001) (Figure 2), while HLA-DPB1*04:02 and HLA-DP rs3117027 G allele were significantly associated with a decreased risk of cervical cancer risk (OR=0.744, 95%CI: 0.652-0.848, Pz=0.001; OR=0.790, 95%CI: 0.743-0.837, Pz=0.001) (Figure 3), and HLA-DP rs9277535 G allele was significantly associated with a decreased risk of cervical cancer risk in Asia (OR=0.802, 95%CI: 0.753-0.855, Pz=0.001) (Figure 4). Though not significant, HLA-DPB1*13:01 showed a tendency of association with an increased risk of cervical cancer in Europe and Asia (OR=1.518, 95%CI: 0.954-2.416, Pz=0.078).

In order to clarify interactions between HLA-DPB1*02:01, DPB1*03:01, DPB1*04:01, DPB1*05:01, and DPB1*13:01 and cervical cancer in Asia, we conducted subgroup analyses based on race system, and we found that HLA-DPB1*13:01 was significantly associated with an increased risk of cervical cancer in Asia (OR=1.834, 95%CI: 1.107-3.039, Pz=0.019) (Figure 5), and though not significant, HLA-DPB1*03:01 showed a tendency of association with an increased risk of cervical cancer in Asia (OR=1.375, 95%CI: 0.987-1.757, Pz=0.061).

The different typing methods used in different laboratories might lead to heterogeneity, so we conducted subgroup analyses based on genotyping method. The results showed that HLA-DPB1*03:01 was significantly associated with an increased risk of cervical cancer (OR=1.354, 95%CI: 1.144-1.604, Pz=0.001) (Figure 2), while HLA-DPB1*04:02 was significantly associated with a decreased risk of cervical cancer risk (OR=0.750, 95%CI: 0.642-0.877, Pz=0.001) (Figure 3), and HLA-DP rs9277535 G allele was significantly associated with a decreased risk of cervical cancer risk in Asia (OR=0.800, 95%CI: 0.740-0.865, Pz=0.001) (Figure 4).

We also found that the following HLA-DP alleles: DPB1*02:01, DPB1*02:02, DPB1*04:01, DPB1*05:01, and DPB1*13:01 were not significantly associated with cervical cancer risk.

3.3. Sensitivity Analysis and Publication Bias. The sensitivity analysis showed that no single study altered the pooled ORs.
Table 2: Meta-analysis of associations between HLA-DP alleles and cervical cancer.

| Alleles       | No. of studies | Case (2n)  | Control (2n) | Heterogeneity P value | \( I^2 \) value (%) for heterogeneity test | Model | OR (95%CI) | P value | Z     | P value for Egger's (Begg's) bias test |
|---------------|----------------|------------|--------------|-----------------------|-------------------------------------------|-------|------------|---------|-------|--------------------------------------|
| DPB1*02:01    | 6              | 743/5916   | 1397/10888   | 0.006                 | 69.1                                      | R     | 0.915 (0.741-1.130) | 0.409   | 0.82  | 0.981 (1.000)                        |
| DPB1*02:02    | 4              | 103/1764   | 132/2300     | 0.071                 | 57.4                                      | R     | 1.261 (0.740-2.148) | 0.394   | 0.85  | 0.107 (0.089)                        |
| DPB1*03:01    | 6              | 652/5878   | 1032/10888   | 0.080                 | 49.1                                      | F     | 1.252 (1.116-1.403) | 0.001   | 3.84  | 0.853 (1.000)                        |
| DPB1*04:01    | 6              | 2015/5892  | 4215/10878   | 0.210                 | 30.1                                      | F     | 1.009 (0.932-1.092) | 0.821   | 0.23  | 0.240 (0.133)                        |
| DPB1*04:02    | 4              | 412/4734   | 1075/9372    | 0.994                 | 0.0                                       | F     | 0.744 (0.652-0.848) | 0.001   | 4.41  | 0.781 (1.000)                        |
| DPB1*05:01    | 5              | 744/3916   | 1031/3248    | 0.007                 | 71.4                                      | F     | 0.953 (0.728-1.248) | 0.727   | 0.35  | 0.129 (0.086)                        |
| DPB1*13:01    | 5              | 177/3840   | 244/10166    | 0.015                 | 67.7                                      | F     | 0.158 (0.954-2.416) | 0.078   | 1.76  | 0.531 (0.806)                        |
| rs4282438-T allele | 4            | 5309/10016 | 12197/18038  | 0.001                 | 90.3                                      | R     | 0.914 (0.688-1.233) | 0.533   | 0.62  | 0.382 (0.734)                        |
| rs9277535 G allele* | 4         | 4268/8266  | 4297/7402    | 0.509                 | 0.0                                       | F     | 0.802 (0.733-0.855) | 0.001   | 6.76  | 0.602 (1.000)                        |
| rs317027-G allele* | 3         | 4994/7588  | 13159/18644  | 0.759                 | 0.0                                       | F     | 0.790 (0.745-0.837) | 0.001   | 7.92  | 0.055 (0.296)                        |
| rs3077-C allele* | 3          | 3494/5613  | 3374/5022    | 0.001                 | 94.7                                      | R     | 0.816 (0.560-1.189) | 0.290   | 1.06  | 0.957 (1.000)                        |

The HLA-DP rs9277535 and rs3077 were just studied among Asian population.
| Alleles               | No. of studies | Case (2n) | Control (2n) | Heterogeneity P value | $I^2$ value (%) for heterogeneity test | Model | OR (95%CI)         | P value | Z     | P value for Egger's (Begg's) bias test |
|----------------------|----------------|-----------|--------------|-----------------------|----------------------------------------|-------|-------------------|---------|-------|----------------------------------------|
| DPB1*02:01           | 4              | 310/1764  | 369/2300     | 0.088                 | 54.1                                   | R     | 1.031 (0.781-1.362) | 0.829   | 0.22  | 0.109 (0.308)                         |
| DPB1*03:01           | 4              | 98/1764   | 98/2300      | 0.228                 | 30.7                                   | F     | 1.317 (0.987-1.757) | 0.061   | 1.87  | 0.570 (0.734)                         |
| DPB1*04:01           | 4              | 112/1764  | 158/2300     | 0.080                 | 55.7                                   | R     | 0.829 (0.524-1.314) | 0.426   | 0.80  | 0.277 (0.308)                         |
| DPB1*05:01           | 4              | 679/1764  | 1012/2300    | 0.034                 | 65.4                                   | R     | 0.874 (0.680-1.123) | 0.291   | 1.06  | 0.358 (0.308)                         |
| DPB1*13:01           | 4              | 150/1764  | 126/2300     | 0.099                 | 52.1                                   | R     | 1.834 (1.107-3.039) | 0.019   | 2.36  | 0.495 (0.734)                         |
### Table 4: Subgroup meta-analysis of associations between HLA-DP alleles and cervical cancer based on genotyping method.

| Alleles      | No. of studies | Genotyping method | Case (2n)   | Control (2n) | Heterogeneity P value | I² value (%) for heterogeneity test | Model | OR (95%CI)              | P value for Egger’s (Begg’s) bias test |
|--------------|----------------|-------------------|-------------|--------------|------------------------|-------------------------------------|-------|-------------------------|----------------------------------------|
| DPB1*02:01  | 5              | PCR               | 506/3764    | 1263/9940    | 0.011                  | 69.2                                | R     | 0.960 (0.749-1.231)    | 0.750                                  |
| DPB1*03:01  | 5              | PCR               | 372/3726    | 908/9940     | 0.355                  | 9.0                                 | F     | 1.354 (1.144-1.604)    | 0.001                                  |
| DPB1*04:01  | 5              | PCR               | 1068/3740   | 3798/9930    | 0.129                  | 43.9                                | F     | 0.951 (0.748-1.210)    | 0.685                                  |
| DPB1*04:02  | 3              | PCR               | 218/2582    | 961/8424     | 0.989                  | 0.0                                 | F     | 0.750 (0.642-0.877)    | 0.001                                  |
| DPB1*05:01  | 4              | PCR               | 679/1764    | 1012/2300    | 0.034                  | 65.4                                | F     | 0.874 (0.680-1.123)    | 0.291                                  |
| rs4282438   | 2              | PCR               | 2244/2496   | 802/8470     | 0.159                  | 49.6                                | F     | 0.842 (0.653-1.087)    | 0.186                                  |
| Rs9277535   | 3              | TaqMan            | 3666/7320   | 3370/6050    | 0.313                  | 13.8                                | F     | 0.800 (0.740-0.865)    | 0.001                                  |
qualitatively, which provided the evidence of the stability of the meta-analysis (Figures 6–9). As shown in Tables 2, 3, and 4, there was no publication bias for any of the alleles.

4. Discussion

Individuals with HPV infection may have distinct results, for example, natural virus clearance, persistent infection with no symptom, or development of premalignant lesion or invasive cancer, even with the same HPV exposure [27–29]. HLA gene polymorphisms, including HLA-DP gene polymorphisms, might be at least one of the reasons for these differences. However, recent studies investigating the association between HLA-DP gene polymorphisms and cervical cancer have been inconsistent. For example, in two GWAS focusing on the investigation of susceptibility loci for cervical cancer in Europe, Chen D reported that HLA-DPB1*04:02 and rs3117027 G allele were significantly associated with a decreased risk of cervical cancer risk, while HLA-DPB1*03:01 was significantly associated with an increased risk of cervical cancer risk, and HLA-DPB1*02:01, DPB1*04:01, DPB1*13:01, and rs4282438 were not associated with cervical cancer risk [10, 11]. However, in another GWAS carried out by Ivansson EL, HLA-DPB1*0201 and DPB1*0402 showed protective effect, and HLA-DPB1*0301, DPB1*0401, and DPB1*0501 showed no significant effect on cervical cancer risk [15]. Furthermore, a GWAS carried out in Chinese showed that HLA-DPB1*03:01 and DPB1*04:01 were associated with susceptibility to cervical cancer, while HLA-DPB1*05:01 and rs4282438 G allele showed protective effects [13]. In addition, in a GWAS investigating susceptibility loci for cervical cancer in Japanese population, HLA-DPB1*02:01, DPB1*02:02, DPB1*03:01, DPB1*04:01, DPB1*04:02, DPB1*05:01, DPB1*13:01, and rs4282438 were not significantly associated with cervical cancer [7]. On the other hand, the associations between HLA-DP rs977535, rs3117027, and rs3077 and cervical cancer risk were inconsistent in Chinese population [8–12, 14].

Meta-analysis is a powerful tool to gather data from individual studies and thus enhance the statistical power of the analysis and reduce random error of false-positive or false-negative associations to obtain reliable results [30]. In the present meta-analysis, a total of 11 studies, including 11 HLA-DP alleles, with at most 5008 cervical cancer cases and 9322 healthy controls, were evaluated. Based on the
results, we found that HLA-DPB1*04:02 and rs3117027 G allele were strongly related to cervical cancer as protective factors (95%CI: 0.652-0.848, Pz=0.001; 95%CI: 0.745-0.837, Pz=0.001), while HLA-DPB1*03:01 might be regarded as risk factors (95%CI: 1.116-1.403, Pz=0.001), which was consistent with the GWAS carried out in China and Europe [12, 13, 15]. In addition, HLA-DP rs9277535 G allele and DPB1*13:01 might be regarded as protective factor (95%CI: 0.753-0.855, Pz=0.001) and risk factor (95%CI: 1.107-3.039, Pz=0.019) of cervical cancer in Asia, respectively, while HLA-DPB1*13:01 was not regarded as risk factor for cervical cancer in the GWAS of cervical cancer in Japanese [7]; that might be related to the relatively small number of cases of the GWAS, thus having low weight. However, HLA-DPB1*02:01, DPB1*02:02, DPB1*04:01, DPB1*05:01, rs4282438, and rs3077 did not show significant associations with cervical cancer in our meta-analysis. In two GWAS, HLA-DPB1*02:01, DPB1*04:01, DPB1*0501, and rs4282438 showed no significant effect on cervical cancer risk [10, 15]. Furthermore, in another GWAS investigating susceptibility loci for cervical cancer in Japanese population, HLA-DPB1*02:01, DPB1*02:02, DPB1*04:01, and rs4282438 were not significantly associated with cervical cancer [7]. All

In order to clarify interactions between HLA-DP gene polymorphisms and cervical cancer in Asia, we conducted a subgroup analysis. The results showed that HLA-DPB1*13:01 was significantly associated with cervical cancer, and HLA-DPB1*03:01 showed a tendency of association with an increased risk of cervical cancer in Asia, while HLA-DPB1*02:01, DPB1*04:01, and DPB1*05:01 were not associated with cervical cancer in Asia either, which implies that some alleles have the same effect in Asia and Europe. The results of subgroup analysis of seven alleles based on genotyping method also showed that HLA-DPB1*03:01 was associated with an increased risk of cervical cancer, and HLA-DPB1*04:02 and rs9277535 G allele were associated with a decreased risk of cervical cancer, which implicated that genotyping method may not affect the results.

Although the correlation of cervical cancer with HLA-DP genes has been demonstrated by various studies, the

| Study ID | PCR | SNP | Overall | OR (95% CI) | Weight |
|----------|-----|-----|---------|-------------|--------|
| Miura K (2016) | 0.74 (0.45, 1.21) | | | 7.22 |
| Chen D (2014) | 0.75 (0.63, 0.89) | | | 61.86 |
| Wu Y (2007) | 0.80 (0.33, 1.96) | | | 2.15 |
| Subtotal (I-squared = 0.0%, p = 0.989) | | | | |
| Ivansson EL (2011) | 0.72 (0.57, 0.93) | | | 28.77 |
| Subtotal (I-squared = .%, p = 0.355) | | | | |
| Overall (I-squared = 0.0%, p = 0.994) | 0.74 (0.65, 0.85) | | | 100.00 |

**NOTE:** Weights are from random effects analysis.

**Figure 3:** Forest plot of effect estimates for DPB1*04:02 polymorphism and cervical cancer risk.
Some limitations existed in the present meta-analysis: First, not all alleles were reported in each study. For example, in a GWAS investigating susceptibility loci for cervical cancer in Han Chinese, the associations of HLA-DPB1*03:01, DPB1*04:01, DPB1*05:01, and DPB1*13:01 with cancer risk were also investigated [13], but we did not include the four alleles in the meta-analysis, because we could not obtain the precise allele frequency. Second, our results were not adjusted. Since age, ethnicity, family history, environmental factors, and HPV infection type are important factors for development of cervical cancer, it is better to conduct the precise analysis adjusted by the above varieties. However, not all studies included have reported age, family history, and the situation of HPV infection, etc. Approximately 200 HPV types have been identified to date, and HPV types are associated with the malignant of disease; for example, HPV types 16 and 18 are responsible for approximately 60%–80% of all cervical cancer cases, while types 31 and 52 account for the majority of the remaining cases [7, 31, 32]. Third, not all alleles were included in the current meta-analysis, such as rs3117027 [8, 10, 11] and rs4282438 of HLA-DPB2 [7, 13]. Finally, some studies included in the meta-analysis took cervical intraepithelial neoplasia III (CINIII) females as cases into analysis. Considering that CINIII is the important stage for developing cervical cancer, we also enrolled it.

5. Conclusion

To the best of our knowledge, no previous meta-analysis has comprehensively assessed the associations between the eleven alleles and cervical cancer risk. Since the number of cases and controls included in the current meta-analysis is relative huge, our results would be relatively reliable, and we could...
| Study ID         | OR (95% CI)   | Weight |
|-----------------|---------------|--------|
| Miura K (2016)  | 0.98 (0.39, 2.45) | 14.43  |
| Yang YC (2015)  | 1.46 (1.10, 1.96) | 29.39  |
| Liang J (2008)  | 2.66 (1.12, 6.29) | 15.50  |
| Wu Y (2007)     | 3.79 (1.53, 9.42) | 14.61  |
| Subtotal (I-squared = 52.1%, p = 0.099) | 1.83 (1.11, 3.04) | 73.92  |
| Chen D (2014)   | 0.87 (0.57, 1.32) | 26.08  |
| Subtotal (I-squared = .%, p = .) | 0.87 (0.57, 1.32) | 26.08  |
| Overall (I-squared = 67.7%, p = 0.015) | 1.52 (0.95, 2.42) | 100.00 |

**NOTE:** Weights are from random effects analysis.

**Figure 5:** Forest plot of effect estimates for DPB1*13:01 polymorphism and cervical cancer risk.

**Figure 6:** Sensitivity analysis of the pooled ORs and 95% CIs for DPB1*03:01 polymorphism.
conclude that HLA-DP gene polymorphisms (DPB1*03:01, DPB1*04:02, DPB1*13:01, rs9277535, and rs3117027) were significantly associated with cervical cancer, which would be regarded as early warning factors. More well-designed large-scale studies including individuals from various countries and regions are still needed to determine the associations between HLA-DP gene polymorphisms and the risk of cervical cancer.

**Disclosure**

The funding source had no involvement in study design, data collection, or data analysis and interpretation.

**Conflicts of Interest**

The authors declared no conflicts of interest.
Authors’ Contributions

Lin Cheng and Peiyuan Xia conceived and designed the experiments, Lin Cheng and Yan Guo performed the experiments and analyzed the data, and Lin Cheng wrote the paper. All authors read and approved the final manuscript.

References

[1] J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, ”Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” *International Journal of Cancer*, vol. 127, no. 12, pp. 2893–2917, 2010.
[2] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, and J. Lortet-Tieulent, ”Global cancer statistics, 2012,” *CA: A Cancer Journal for Clinicians*, vol. 65, no. 2, pp. 87–108, 2015.
[3] N. Munoz, ”Human papillomavirus and cancer: the epidemiological evidence,” *Journal of Clinical Virology*, vol. 19, no. 1–2, pp. 1–5, 2000.
[4] M. Schiffman, A. G. Glass, N. Wentzensen et al., ”A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser cohort study,” *Cancer Epidemiology, Biomarkers & Prevention*, vol. 20, no. 7, pp. 1398–1409, 2011.
[5] M. Stanley, ”Immune responses to human papillomavirus,” *Vaccine*, vol. 24, supplement 1, pp. S16–S22, 2006.
[6] A. M. Mehta, M. Mooij, I. Branković, S. Ouburg, S. A. Morré, and E. S. Jordanova, ”Cervical Carcinogenesis and Immune Response Gene Polymorphisms: A Review,” *Journal of Immunology Research*, vol. 2017, Article ID 8913860, 2017.
[7] K. Miura, H. Mishima, M. Yasunami et al., ”A significant association between rs8067378 at 17q12 and invasive cervical cancer originally identified by a genome-wide association study in Han Chinese is replicated in a Japanese population,” *Journal of Human Genetics*, vol. 61, no. 9, pp. 793–796, 2016.
[8] M. Jia, J. Han, D. Hang et al., ”HLA-DP is the cervical cancer susceptibility loci among women infected by high-risk human papillomavirus: potential implication for triage of human papillomavirus-positive women,” *Tumor Biology*, vol. 37, no. 6, pp. 8019–8025, 2016.
[9] Y.-C. Yang, T.-Y. Chang, T.-C. Chen, W.-S. Lin, S.-C. Chang, and Y.-J. Lee, ”Genetic susceptibility to cervical squamous cell carcinoma is associated with HLA-DPβ1 polymorphisms in Taiwanese women,” *Cancer Immunology, Immunotherapy*, vol. 64, no. 9, pp. 1151–1157, 2015.
[10] D. Chen and U. Gyllensten, ”Systematic investigation of contribution of genetic variation in the HLA-DP region to cervical cancer susceptibility,” *Carcinogenesis*, vol. 35, no. 8, pp. 1765–1769, 2014.
[11] D. Chen, I. Juko-Pecirep, J. Hammer et al., ”Genome-wide association study of susceptibility loci for cervical cancer,” *Journal of the National Cancer Institute*, vol. 105, no. 9, pp. 624–633, 2013.
[12] J. Jiang, N. Li, Y. Shen et al., ”Genetic variants in HLA-DP/DQ contribute to risk of cervical cancer: A two-stage study in Chinese women,” *Gynecologic Oncology*, vol. 129, no. 2, pp. 401–405, 2013.
[13] Y. Shi, L. Li, Z. Hu et al., ”A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12,” *Nature Genetics*, vol. 45, no. 8, pp. 918–922, 2013.
[14] K. Zhang, P. Sun, L. W. Guo et al., ”Association study on genetic polymorphisms of HLA-DP/DQ and susceptibility to cervical cancer in North Chinese women,” *China Cancer*, vol. 22, pp. 442–447, 2013 (Chinese).
[15] E. L. Ivansson, I. Juko-Pecirep, H. A. Erlich, and U. B. Gyllensten, ”Pathway-based analysis of genetic susceptibility to cervical cancer in situ: HLA-DPβ1 affects risk in Swedish women,” *Genes & Immunity*, vol. 12, no. 8, pp. 605–614, 2011.
[16] J. Liang, A. Xu, Y. Xie, A. O. Awonuga, and Z. Lin, ”Some but not all of HLA-II alleles are associated with cervical cancer in Chinese women,” *Cancer Genetics and Cyto genetics*, vol. 187, no. 2, pp. 95–100, 2008.
[17] Y. Wu, B. Liu, W. Lin et al., ”Human Leukocyte Antigen Class II Alleles and Risk of Cervical Cancer in China,” *Human Immunology*, vol. 68, no. 3, pp. 192–200, 2007.
[18] R. Horton, L. Wilming, V. Rand et al., “Gene map of the extended human MHC,” *Nature Reviews Genetics*, vol. 5, no. 12, pp. 889–899, 2004.

[19] P. S. de Araujo Souza, L. Sichero, and P. C. Maciag, “HPV variants and HLA polymorphisms: The role of variability on the risk of cervical cancer,” *Future Oncology*, vol. 5, no. 3, pp. 359–370, 2009.

[20] A. Hildesheim and S. S. Wang, “Host and viral genetics and risk of cervical cancer: a review,” *Virus Research*, vol. 89, no. 2, pp. 229–240, 2002.

[21] M. M. Madeleine, L. G. Johnson, A. G. Smith et al., “Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRBI, and HLA-DQBI loci and squamous cell cervical cancer risk,” *Cancer Research*, vol. 68, no. 9, pp. 3532–3539, 2008.

[22] Y. Hu, J.-Z. Wu, H. Zhu et al., “Association of HLA-DRBI, HLA-DQBI Polymorphisms with HPV 16 E6 Variants among Young Cervical Cancer Patients in China,” *Journal of Cancer*, vol. 8, no. 12, pp. 2401–2409, 2017.

[23] P. J. Leo, M. M. Madeleine, S. Wang et al., “Defining the genetic susceptibility to cervical neoplasia—A genome-wide association study,” *PLoS Genetics*, vol. 13, no. 8, Article ID e1006866, 2017.

[24] X. Sun, Y. Liu, M. Li, M. Wang, and Y. Wang, “Involvement of miR-485-5p in hepatocellular carcinoma progression targeting EMMPRIN,” *Biomedicine & Pharmacotherapy*, vol. 72, pp. 58–65, 2015.

[25] X. Zhang, L. Zhang, C. Tian, L. Yang, and Z. Wang, “Genetic variants and risk of cervical cancer: epidemiological evidence, meta-analysis and research review,” *BJOG: An International Journal of Obstetrics and Gynaecology*, vol. 121, no. 6, pp. 664–674, 2014.

[26] L.-Z. Wei, H.-L. Wang, X. Liu et al., “Meta-analysis on the relationship between HLA-DRB1 gene polymorphism and cervical cancer in Chinese population,” *PLoS ONE*, vol. 9, no. 2, Article ID e88439, 2014.

[27] S. de Sanjosé, M. Diaz, X. Castellsagué et al., “Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis,” *The Lancet Infectious Diseases*, vol. 7, no. 7, pp. 453–459, 2007.

[28] X. Carcopino, N. Bolger, M. Henry et al., “Evaluation of type-specific HPV persistence and high-risk HPV viral load quantitation in HPV positive women under 30 with normal cervical cytology,” *Journal of Medical Virology*, vol. 83, no. 4, pp. 637–643, 2011.

[29] F. Broccolo, L. Fusetti, and L. Ceccherini-Nelli, “Is it true that pre-conization high-risk HPV DNA load is a significant factor of persistence of HPV infection after conization?” *Journal of Clinical Virology*, vol. 55, no. 4, pp. 377–378, 2012.

[30] J. Wang, H.-F. Pan, Y.-T. Hu, Y. Zhu, and Q. He, “Polymorphism of IL-8 in 251 allele and gastric cancer susceptibility: A meta-analysis,” *Digestive Diseases and Sciences*, vol. 55, no. 7, pp. 1818–1823, 2010.

[31] W. I. Al-Daraji and J. H. F. Smith, “Infection and cervical neoplasia: facts and fiction,” *International Journal of Clinical and Experimental Pathology*, vol. 2, no. 1, pp. 48–64, 2009.

[32] B. Cao, X. Tian, Y. Li et al., “LMP7/TAP2 gene polymorphisms and HPV infection in esophageal carcinoma patients from a high incidence area in China,” *Carcinogenesis*, vol. 26, no. 7, pp. 1280–1284, 2005.